Drug Discovery CRO
Total Trials
11
As Lead Sponsor
As Collaborator
0
Total Enrollment
661
NCT04207801
A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 21, 2020
Completion: Apr 15, 2021
NCT04855721
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
Start: May 4, 2021
Completion: Dec 10, 2022
NCT05607199
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Phase: Phase 1
Start: Sep 16, 2022
Completion: Oct 16, 2026
NCT05605119
First in Human, Dose Escalation, Dose Expansion Study of AUR105
Start: Nov 30, 2022
Completion: May 30, 2026
NCT05861947
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Start: Aug 26, 2023
Completion: Jun 30, 2025
NCT05865002
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Start: Sep 5, 2023
Completion: Jun 30, 2027
NCT05984147
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
Start: Oct 19, 2023
Completion: Aug 30, 2027
NCT06760702
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers
Start: Nov 9, 2024
Completion: May 31, 2027
NCT06761586
A Study of AUR104 in Patients with Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
Start: Dec 12, 2024
Completion: Jan 4, 2027
NCT06755450
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Start: Jan 15, 2025
Completion: Jan 15, 2028
NCT07040059
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase: Phase 1/2
Start: Mar 22, 2025
Completion: Nov 30, 2028
Loading map...